Clinical Trial Update: Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SHR-1209 in combination with lipid-lowering agents for hypercholesterolemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Hyperlipidemia
• Non-familial Hypercholesterolemia

Drugs mentioned

• SHR-1209

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-familial Hypercholesterolemia, Mixed Hyperlipidemia | Phase 3 | Status: COMPLETED